OQPBIOM

What OQPBIOM does

OQPBioM (오큐피바이오엠) is a private, pre-revenue biopharmaceutical company headquartered in Pyongtaek, South Korea, specializing in the development of novel immuno-oncology therapies for cancer. The company is focused on three high-unmet-need oncology indications — ovarian cancer, pancreatic cancer, and metastatic breast cancer — and operates its pipeline through a subsidiary structure holding multiple immunotherapy programs targeting these diseases. Its core competency is monoclonal antibody-based immunotherapy development using immune checkpoint modulation strategies.

The company's lead asset is Oregovomab, a monoclonal antibody immunotherapy for ovarian cancer that demonstrated excellent safety and efficacy in Phase 2 clinical trials and received recognition in leading international gynecological oncology journals. In the second half of 2020, OQPBioM initiated the FDA global Phase 3 clinical trial (FLORA-5) for Oregovomab, positioning the asset as a potential first-in-class immunotherapy for ovarian cancer. The secondary asset, AR20.5, is an immuno-oncology candidate targeting pancreatic cancer and is part of the broader three-indication pipeline. The underlying technology is rooted in proprietary monoclonal antibody design, supported by registered patent/trademark filings on both Oregovomab and AR20.5.

As a development-stage biotech, OQPBioM has not yet generated revenue from product commercialization. Its expected future revenue model is based on drug commercialization, licensing agreements, or strategic partnerships with larger pharmaceutical companies following regulatory approval. In June 2025 the company executed an acquisition of Adbiotech and received an investment from Quest PharmaTech, signaling continued capital deployment and inorganic expansion. The company communicates its pipeline and corporate information through its corporate website (www.oqpbiom.com) and an active IR/PR announcement section, targeting investors, healthcare professionals, and potential partners.

Name

OQPBIOM

Legal name

오큐피바이오엠

Website

https://oqpbiom.com

Company type

Private

Operating status

Operating

Short description

OQPBioM (오큐피바이오엠) is a private South Korean biopharmaceutical company developing monoclonal antibody immuno-oncology therapies for ovarian, pancreatic, and metastatic breast cancer, with lead candidate Oregovomab currently in an FDA global Phase 3 trial (FLORA-5).

Ownership category

akta.pro rank

Product category

Immuno-oncology biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• Immuno-oncology drug development
• Monoclonal antibody therapy
• Ovarian cancer immunotherapy
• Pancreatic cancer treatment
• Biopharmaceutical R&D

Headquarters

HQ city

Pyongtaek

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing immunotherapy drugs for cancer treatment. Expected future revenue through drug commercialization, licensing agreements, and/or strategic partnerships with larger pharmaceutical companies upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

OQPBioM (오큐피바이오엠) is a pre-revenue, development-stage biopharmaceutical company that researches and develops monoclonal antibody-based immuno-oncology drug candidates for solid tumors. Its pipeline targets ovarian cancer (lead asset Oregovomab, in FDA global Phase 3 FLORA-5 trial initiated in 2H 2020), pancreatic cancer (AR20.5), and metastatic breast cancer, with future revenue expected from drug licensing or commercialization following regulatory approval.

Product overview

OQPBIOM is a biotech company specializing in immune-oncology cancer treatment development. The company operates a unified platform focused on cancer immunotherapy, with two named products in their pipeline: Oregovomab for ovarian cancer (Phase 3) and AR20.5 for pancreatic cancer. The company is also developing treatments for metastatic breast cancer. These products are part of a coordinated research portfolio targeting multiple cancer indications using immune-oncology approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• Oregovomab (오레고보맙) Monoclonal antibody immunotherapy drug candidate for ovarian cancer, representing the first immunotherapy developed for this indication. Demonstrated excellent safety and efficacy in Phase 2 clinical trials and is currently progressing through FDA global Phase 3 clinical trial (FLORA-5) initiated in second half of 2020.
• AR20.5 Innovative immune-oncology therapeutic candidate targeting pancreatic cancer, part of the company's pipeline targeting multiple cancer types through cancer antigen-directed immunotherapy.

Quantifiable outcome

• Oregovomab demonstrated excellent safety and efficacy in Phase 2 clinical trials

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Emerging players

• Ottimo Pharma: Biotech focused on immuno-oncology antibody development; comparable as a smaller emerging player in monoclonal antibody cancer therapeutics with similar scale and stage.
• Genmab: Antibody therapeutics company developing monoclonal antibody oncology candidates using proprietary platforms; comparable as a monoclonal antibody developer in oncology, though broader than OQPBIOM's focus.

Direct peers

• Clovis Oncology: Developer of Rubraca (rucaparib), a PARP inhibitor approved for ovarian cancer; directly comparable as a targeted therapy developer competing for ovarian cancer share.
• ImmunoGen: Developer of Elahere (mirvetuximab soravtansine), an ADC approved for ovarian cancer; directly comparable as a focused ovarian cancer therapeutic developer with overlapping indication.
• Quest PharmaTech: Canada-based immuno-oncology company and OncoQuest parent that invested in OQPBIOM in June 2025; shares the same Oregovomab development lineage and ovarian cancer immunotherapy focus.
• OncoQuest Pharmaceuticals: Canadian immuno-oncology company that originally developed and held rights to Oregovomab; a direct peer and historical development partner for OQPBIOM's lead asset in ovarian cancer immunotherapy.

Broad incumbents

• AstraZeneca: Major pharma with the leading PARP inhibitor Lynparza in ovarian cancer and broader immuno-oncology franchise; the dominant broad incumbent OQPBIOM would compete against if approved.
• Bristol-Myers Squibb: Owns Opdivo (nivolumab), one of the leading checkpoint inhibitor immunotherapies across multiple cancers including ovarian; a broad incumbent OQPBIOM competes against in the immuno-oncology category.

Regional players

• PharmaEngine: Taiwan-based oncology specialty pharma developing and licensing cancer therapeutics across Asia; a comparable regional oncology player with similar development-stage profile and APAC market focus.
• Genexine: South Korean clinical-stage biotech developing immuno-oncology and other biologics; comparable Korean peer with similar development-stage profile and biotech operating model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OQPBIOM